Citigroup’s Grace Therapeutics GRCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$76.3K Buy
+35,481
New +$78.7K ﹤0.01% 4561
2025
Q4
– Sell
-2,757
Closed -$8.19K – 6586
2025
Q3
$8.19K Buy
2,757
+2,756
+275,600% +$8.64K ﹤0.01% 5081
2025
Q2
$3 Buy
+1
New +$3 ﹤0.01% 5605
2016
Q2
– Sell
-5
Closed – – 7490
2016
Q1
$0 Buy
5
+4
+400% +$313 ﹤0.01% 7812
2015
Q4
$0 Buy
+1
New +$118 ﹤0.01% 7912
2015
Q3
– Sell
-1
Closed – – 7765
2015
Q2
$0 Buy
+1
New +$186 ﹤0.01% 7792
2015
Q1
– Sell
-3
Closed -$1K – 7476
2014
Q4
$1K Buy
3
+2
+200% +$492 ﹤0.01% 7004
2014
Q3
$0 Sell
1
-16
-94% -$7.52K ﹤0.01% 7340
2014
Q2
$8K Sell
17
-4
-19% -$1.91K ﹤0.01% 6275
2014
Q1
$12K Buy
+21
New +$12.8K ﹤0.01% 6268

Other funds holding GRCE

Citigroup's GRCE Position: Q3 2026 in Review

Citigroup opened a new position in Grace Therapeutics (GRCE) in Q3 2026: 35,481 shares worth $76.3K. The stake represents ﹤0.01% of the portfolio and ranks #4561 among its holdings. This is a return to the name: Citigroup previously reported a position in GRCE as recently as Q3 2025.

Citigroup first reported a position in GRCE in Q1 2014 and has held it in 10 quarters since. 37 funds tracked by Wall St. Rank hold GRCE as of Q3 2026.

  • Citigroup held 35,481 shares of Grace Therapeutics worth $76.3K as of Q3 2026.
  • Grace Therapeutics was a new Citigroup position in Q3 2026.
  • Grace Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4561 holding.
  • Citigroup first reported a position in Grace Therapeutics in Q1 2014 and has held it in 10 quarters since.
  • 37 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.